OTLK icon

Outlook Therapeutics
OTLK

Overview Fund Activity

12 hedge funds and large institutions have $5.09M invested in Outlook Therapeutics in 2018 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 0 closing their positions.

Holders
12
Holders Change
+1
Holders Change %
+9.09%
% of All Funds
0.27%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
4
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Vanguard Group
1
Vanguard Group
Pennsylvania
$561K
2
Susquehanna International Group
2
Susquehanna International Group
Pennsylvania
$152K
3
Bank of America
3
Bank of America
North Carolina
$12K

Top Sellers

1
SM
1
Sabby Management
Florida
$3.32M
2
PAM
2
Panagora Asset Management
Massachusetts
$37K
3
TSS
3
Two Sigma Securities
New York
$18K
4
UBS Group
4
UBS Group
Switzerland
$7K
Name Market Value Shares Shares
Change 		Shares
Change %
SM
1
Sabby Management
Florida
$3.32M 3,354,909 -337,828 -9%
ACA
2
Avoro Capital Advisors
New York
$670K 683,531 – –
Vanguard Group
3
Vanguard Group
Pennsylvania
$561K 572,805 +263,768 +85%
MWNA
4
Marshall Wace North America
New York
$257K 261,800 – –
Susquehanna International Group
5
Susquehanna International Group
Pennsylvania
$152K 155,019 +155,019 New
PAM
6
Panagora Asset Management
Massachusetts
$37K 37,293 -22,794 -38%
ACP
7
Acuta Capital Partners
California
$29K 29,082 – –
TSS
8
Two Sigma Securities
New York
$18K 18,341 -4,464 -20%
Morgan Stanley
9
Morgan Stanley
New York
$16K 16,011 – –
Bank of America
10
Bank of America
North Carolina
$12K 12,467 +2,467 +25%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$10K 11,165 – –
UBS Group
12
UBS Group
Switzerland
$7K 8,086 -2,000 -20%
CFGS
13
Concourse Financial Group Securities
Alabama
– – – –